SavedAdd your journal

Journals / Akdeniz Tıp Dergisi / 2021 / Cilt: 7 - Sayı: 3

Is GnRH agonist protocol as effective as GnRH antagonist protocol in IVF cycles?

GnRH agonist protokol IVF sikluslarında GnRH antagonist protokol kadar etkin midir?

Ruşen AYTAÇ
Seda ŞAHİN AKER
Pages
415–423
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results Daily dose of gonadotrophin (249±82,87) and cycle cancellation rates were more common in GnRH antagonist group (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective Aim of this study is to compare effectiveness of gonadotrophin releasing hormone (GnRH) agonist in-vitro fertilisation(IVF) cycles compared to GnRH antagonist IVF cycles.
📊
Key Findings & Data:MethodsPatient’s records were retrospectively evaluated 283 GnRH agonist and 717 GnRH antagonist fresh cycles were compared.
💡
Conclusion & Impact:Results Daily dose of gonadotrophin (249±82,87) and cycle cancellation rates were more common in GnRH antagonist group (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective Aim of this study is to compare effectiveness of gonadotrophin releasing hormone (GnRH) agonist in-vitro fertilisation(IVF) cycles compared to GnRH antagonist IVF cycles. MethodsPatient’s records were retrospectively evaluated 283 GnRH agonist and 717 GnRH antagonist fresh cycles were compared. Results Daily dose of gonadotrophin (249±82,87) and cycle cancellation rates were more common in GnRH antagonist group (p

Özet

Giriş ve Amaç:İn vitro fertilizasyon-embriyo transferi( IVF-ET ) uygulanan 1000 siklusun GnRH antagonist veagonist protokollerinin etkinliğinin karşılaştırılması amaçlanmıştır.Gereç ve Yöntemler:Retrospektif tarama ile 1000 siklus çalışmaya dahil edilmiştir, bu siklusların 283’üne agonistprotokol, 717’sine antagonist protokol uygulanmıştır.Bulgular:Antagonist protokol grubunda günlük kullanılan ortalama gonadotropin dozu 249±82,87 IU vesiklus iptal oranları anlamlı derecede yüksekti (p

🔖

Cite This Article

AYTAÇ, R., AKER, S. Ş. (2022). Is GnRH agonist protocol as effective as GnRH antagonist protocol in IVF cycles?. Akdeniz Tıp Dergisi, Cilt: 7 - Sayı: 3, 415–423. https://ajindex.com/articles/434273

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Gnoth C, Godehardt D, Godehardt E, Frank-Herrmann P, Freundl G. Time to pregnancy: results of the German prospective study and impact on the management of infertility. Hum Reprod 2003;18: 1959-66
  2. Vayena E, Rowe PJ,P.Griffin PD. Current Practices and Controversies in Assisted Reproduction. WHO Press 2002;83-101
  3. Steptoe PC, Edwards RG. Reimplantation of a human embryo with subsequent tubal pregnancy. Lancet;1976;31:750-751
  4. Steptoe PC, Edwards RG. Birth after reimplantation of a human embryo. Lancet;1978;12;2:366
  5. Janssens RM, Brus L,Cahill DJ,Huirne JA,Schoemaker J,Lambalk CB. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000;6:505-18
  6. ART factsheet. European Society of Human Reproduc tion and Embryology. 2014
  7. Daya S, Maheshwari A, Siristatidis CS, Bhattacharya S, Gibreel AF. Gonadotropin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertiliza tion and gamete intrafallopian transfer cycles. Cochrane Database Systematic Review, 2000;(2):CD001299
  8. Sunkara SK, Coomarasamy A, Faris F,Braude P, Khalaf Y. Long gonadotropn-releasing hormone agonist versus short agonist versus antagonist regimens in poorrespond ers undergoing in in vitro fertilization: a randomized controlled trial. Fertil Steril 2014; 101(1):147–153
  9. Albuquerque LE, Tso LO, Saconato H, Albuquerque MC, Macedo CR. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013;1:CD002808
  10. Assisted Reproductive Technology National Summary Report. National Center for Chronic Disease Prevention and Health Promotion.2012;1:82 (https://www.cdc.gov /art/pdf/2012-report/art-2012-fertility-clinic-report.pdf)
  11. CARTR Plus 2013 Report. The Canadian Assisted Repro ductive Technologies Register(CARTR). (https://cfas. ca/cartr-annual-reports.html)
  12. Wang YA, Healy D, Black D, Sullivan AD. Age-specific success rate for women undertaking their first assisted reproduction technology treatment using their own oocytes in Australia, 2002– 2005. Hum Reprod. 2008; 23(7):1633-8. 13. van Loendersloot LL, van Wely M, Limpens J, Bossuyt PM, Repping S. Predictive factors in in vitro fertiliza tion(IVF): a systematic review and meta-analysis. Hum Reprod Update. 2010;16(6):577-89
  13. Gesink Law DC, Maclehose RF, Longnecker MP. Obesi ty and time to pregnancy. Hum Reprod 2007;22(2):414–420.